NN6435-4697
Dose response and safety of an oral PCSK9-i, NNC0385-0434, in patients with very high or high cardiovascular risk on maximally tolerated statin treatment requiring further LDL-C reduction
- Stage
- klaar
- Medicine
- NNC0385-0434 (oraal PCSK9-i)
- Population
- ASCVD
- Phase
- II
- First Patient In
- 8 November 2021
- Last Patient In
- 28 January 2022
- Last Patient Last Visit
- 18 June 2022
Study Director
prof. dr. F.M.A.C. Martens
Cardioloog
Office Contact
